Soeda Emiko, Ferran Maureen C, Baker Carl C, McBride Alison A
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, MD 20892, USA.
Virology. 2006 Jul 20;351(1):29-41. doi: 10.1016/j.virol.2006.03.016. Epub 2006 Apr 19.
HPV16 DNA is often integrated in cancers, disrupting the E1 or E2 genes. E2 can repress the E6/E7 promoter, but other models have been proposed to explain why integration promotes malignant progression. E1 and E2 are required for viral replication, and so genetic analysis of their role in transcriptional regulation is complex. Therefore, we developed an extrachromosomal vector containing HPV16 to undertake a genetic analysis of the E1 and E2 genes. We demonstrate that the E2 protein is primarily a transcriptional repressor when expressed from the virus. Furthermore, repression requires both the transactivation function of E2 and specific binding of E2 to the LCR. We find no evidence that the E1 protein directly modulates HPV16 gene expression. However, certain E1 mutations modulated transcription indirectly by altering splicing of E2 mRNA species. These data provide important insight into which E1 and E2 functions are optimal targets for anti-viral therapies.
人乳头瘤病毒16型(HPV16)的DNA在癌症中常发生整合,从而破坏E1或E2基因。E2可抑制E6/E7启动子,但也有人提出了其他模型来解释整合为何会促进恶性进展。E1和E2是病毒复制所必需的,因此对它们在转录调控中作用的遗传分析很复杂。因此,我们构建了一个含有HPV16的染色体外载体,以对E1和E2基因进行遗传分析。我们证明,当从病毒中表达时,E2蛋白主要是一种转录抑制因子。此外,抑制作用既需要E2的反式激活功能,也需要E2与长控区(LCR)的特异性结合。我们没有发现E1蛋白直接调节HPV16基因表达的证据。然而,某些E1突变通过改变E2 mRNA种类的剪接间接调节转录。这些数据为哪些E1和E2功能是抗病毒治疗最佳靶点提供了重要见解。